Andere talen Clene Inc.

Aandelen

CLNN

US1856341029

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,4367 ^USD	-0,07%		+26,03%	+47,24%

16/04	Clene Inc. en Clene Nanomedicine, Inc. Presenteerden de resultaten van de Fase 2 VISIONARY-MS Long Term Extension (LTE) studie op de jaarlijkse bijeenkomst van de American Academy of Neurology (AAN) in Denver in 2024.	CI
15/03	Clene Inc. kondigt een door vakgenoten beoordeelde publicatie aan over de proteïnecorona van het onderzoeksgeneesmiddel tegen neurodegeneratieve ziekten, CNM-Au8	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	01/05
Clene : 2023 Annual Report to Stockholders	17/04
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	16/04
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	16/04
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	19/03
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	15/03
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	15/03
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	13/03
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
North American Morning Briefing : Stock Futures -2-	11/03
Clene to Present at the 36th Annual ROTH Conference	07/03
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	29/02
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	22/02
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	22/02
Clene Inc. announces positive results from CNM-Au8 results from MS trial	05/02
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	08/01
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	08/01
US FDA finds Clene's trial data for ALS drug to be insufficient	21/12
Clene Provides Update on ALS Clinical Development Meeting With FDA	21/12
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Clene Inc.

Aandelen

CLNN

US1856341029

Andere talen

Filters